An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Camrelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 06 Jun 2017 Results (n=58) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 14 Dec 2016 Planned number of patients changed from 36 to 96.
- 14 Dec 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.